Subscription Required

Only paid subscribers* to Specialty Pharmacy News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Specialty Pharmacy News receive

  • 12 monthly issues packed with news and strategies on this increasingly vital sector in health business, delivered First Class by U.S. Mail and electronically (optional),
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest and hot topic articles grouped for convenient reading, and
    • Regular postings from Managing Editor Angela Maas.
View a sample and get more information
July 2015

Recent Stories of Interest

From Specialty Pharmacy News - As Aetna Inc. continues to transition to a value-based rather than fee-for-service approach, the insurer unveiled that it’s partnering with the University of Chicago Medicine on an oncology medical home. Through the arrangement, which began July 1, the groups hope to impact increasing health care costs, inefficient care and redundant services. Among the operating principles are the following: “An orientation to the whole person”: A UChicago Medicine physician will oversee arrangements with other providers to take care of all of a patient’s needs. Read more

Diplomat Pharmacy, Inc. continues to boost its specialty pharmacy presence through acquisitions.… Read more

When Gilead Sciences, Inc.’s hepatitis C drug Harvoni (ledipasvir/sofosbuvir) came onto the… Read more

A class of drugs that traditionally has had only nonspecialty medications available… Read more

From the Editor

Welcome to your Specialty Pharmacy News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with your comments on the last issue of Specialty Pharmacy News, story ideas for future issues, or any other suggestions you have that can make the newsletter more useful for you.

July 24, 2015
FDA Approves Sanofi-Aventis/Regeneron PCSK9 Inhibitor

FDA approves Sanofi-Aventis/Regeneron PCSK9 inhibitor Praluent for use in adults with heterozygous familial hypercholesterolemia or ones with conditions requiring additional lowering of LDL cholesterol

July 24, 2015
FDA OKs Label Expansion for Kyprolis

FDA grants another indication to Onyx Pharmaceuticals’ Kyprolis (carfilzomib) to treat people with relapsed multiple myeloma

July 24, 2015
FDA Approves Novartis Skin Cancer Drug

FDA approves Novartis’ Odomzo (sonidegib) to treat people with locally advanced basal cell carcinoma that has recurred after surgery or radiation or in people who are not candidates for surgery or radiation

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?